KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non Operating Income (2016 - 2025)

Regeneron Pharmaceuticals has reported Non Operating Income over the past 17 years, most recently at $132.2 million for Q4 2025.

  • Quarterly results put Non Operating Income at $132.2 million for Q4 2025, up 272.14% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (up 116.53% YoY), and the annual figure for FY2025 was $1.7 billion, up 109.43%.
  • Non Operating Income for Q4 2025 was $132.2 million at Regeneron Pharmaceuticals, down from $755.8 million in the prior quarter.
  • Over the last five years, Non Operating Income for REGN hit a ceiling of $755.8 million in Q3 2025 and a floor of -$197.4 million in Q1 2022.
  • Median Non Operating Income over the past 5 years was $126.1 million (2023), compared with a mean of $157.6 million.
  • Biggest five-year swings in Non Operating Income: crashed 336.63% in 2021 and later soared 1844.51% in 2022.
  • Regeneron Pharmaceuticals' Non Operating Income stood at -$136.3 million in 2021, then surged by 274.1% to $237.3 million in 2022, then crashed by 49.43% to $120.0 million in 2023, then tumbled by 164.0% to -$76.8 million in 2024, then skyrocketed by 272.14% to $132.2 million in 2025.
  • The last three reported values for Non Operating Income were $132.2 million (Q4 2025), $755.8 million (Q3 2025), and $442.8 million (Q2 2025) per Business Quant data.